P95

Their core work

P95 is a Leuven-based epidemiology and vaccine research SME that evaluates how well vaccines work in real-world populations — translating clinical trial data into public health evidence. They combine observational study design, disease burden estimation, and health economic modelling to help policymakers and public health bodies make evidence-based vaccination decisions. In H2020, they contributed to large public-private consortia assessing influenza vaccine effectiveness and understanding how immunity changes with age. Their output is typically quantitative: effectiveness estimates, cost-benefit analyses, and impact models that regulators, health agencies, and vaccine developers can act on.

What they specialise in

How they've shifted over time

P95's early H2020 work (DRIVE, from 2017) focused on the mechanics and governance of measuring influenza vaccine effectiveness — how do you run rigorous real-world studies, who coordinates them, and how do public and private actors collaborate? By 2019, with VITAL, their focus shifted toward the biology of aging and its effect on immunity, and added a health economics dimension (cost-benefit analyses, impact modelling) alongside behavioural elements like communication and education. The trend is from methodology and governance toward application in a specific high-need population: older adults with declining immune function.

P95 is moving from general vaccine effectiveness methodology into the more specialised field of vaccinology for aging populations, with growing capability in health economic evaluation — a direction well-aligned with EU priorities on healthy aging and pandemic preparedness.

How they like to work

P95 always joins as a participant, never as project coordinator — signalling that they operate as a specialist contributor rather than a consortium architect. Despite only two projects, they have accumulated 37 unique consortium partners across 13 countries, implying they join large, multi-partner RIA consortia (roughly 18–19 partners per project). This profile suggests they are brought in for a specific technical function — most likely epidemiological analysis or modelling — within broader multi-disciplinary health research teams.

P95 has built a surprisingly broad network for a two-project SME: 37 unique partners spanning 13 countries across Europe. Their home country of Belgium and the wider European health research ecosystem appear to be their primary collaboration space, consistent with the RIA funding scheme which typically draws pan-European consortia.

What sets them apart

P95 occupies a rare position as a private-sector SME specialised in vaccine epidemiology — a field dominated by academic institutions and public health agencies. This gives them the methodological depth of a research organisation with the agility and applied focus of a consultancy. For consortium builders, they offer a credible, non-academic partner who bridges rigorous study design and real-world health system evidence, which is particularly valuable for satisfying both scientific and policy relevance requirements in health RIAs.

Highlights from their portfolio

• DRIVE
  The largest funding award for P95 (€674,315) and their foundational project, establishing their role in pan-European influenza vaccine effectiveness research under a public-private governance framework.
• VITAL
  Demonstrates P95's expansion into immunosenescence and health economics, positioning them at the intersection of aging population health and vaccine policy — a strategically important niche as Europe's population ages.